MX2022001947A - Anticuerpos que se unen a las proteinas lrp5 y metodos de uso. - Google Patents

Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.

Info

Publication number
MX2022001947A
MX2022001947A MX2022001947A MX2022001947A MX2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
lrp5 proteins
bind lrp5
bind
Prior art date
Application number
MX2022001947A
Other languages
English (en)
Spanish (es)
Inventor
Jagath R Junutula
Stephane Angers
Sachdev Sidhu
Guohua Pan
Nish Patel
Jason Moffat
Jarrett Adams
Original Assignee
Modmab Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modmab Therapeutics Inc filed Critical Modmab Therapeutics Inc
Publication of MX2022001947A publication Critical patent/MX2022001947A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022001947A 2019-08-14 2020-08-14 Anticuerpos que se unen a las proteinas lrp5 y metodos de uso. MX2022001947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962886913P 2019-08-14 2019-08-14
PCT/CA2020/051119 WO2021026665A1 (en) 2019-08-14 2020-08-14 Antibodies that bind to lrp5 proteins and methods of use

Publications (1)

Publication Number Publication Date
MX2022001947A true MX2022001947A (es) 2022-06-14

Family

ID=74570326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001947A MX2022001947A (es) 2019-08-14 2020-08-14 Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.

Country Status (10)

Country Link
US (1) US20230183336A1 (https=)
EP (1) EP4013791A4 (https=)
JP (1) JP7840842B2 (https=)
KR (1) KR20220078568A (https=)
CN (2) CN119798435A (https=)
AU (1) AU2020329092A1 (https=)
CA (1) CA3147827A1 (https=)
IL (1) IL290509A (https=)
MX (1) MX2022001947A (https=)
WO (1) WO2021026665A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4547713A2 (en) * 2022-06-30 2025-05-07 The University of Chicago Cd73 (nt5e) targeting polypeptides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
US9200072B2 (en) * 2012-01-18 2015-12-01 Genentech Inc. Anti-LRP5 antibodies and methods of use
US20190194314A1 (en) * 2012-12-21 2019-06-27 Stowers Institute For Medical Research Antibodies for modulating binding between lrp and wise
US10294294B2 (en) * 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
UA122079C2 (uk) * 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
CA3077518C (en) * 2016-09-07 2021-10-19 Frederic Fellouse Synthetic antibodies against vegf and their uses
EP3630816B1 (en) * 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
EP3700930A1 (en) * 2017-10-25 2020-09-02 The Regents of the University of California Antibodies against cdcp1 for the treatment and detection of cancer
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7550647B2 (ja) * 2018-02-14 2024-09-20 アントレラ セラピューティクス インコーポレイテッド Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用
US10640562B2 (en) * 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
CA3111087A1 (en) * 2018-08-29 2020-03-05 Nanjing Legend Biotech Co., Ltd. Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof

Also Published As

Publication number Publication date
US20230183336A1 (en) 2023-06-15
CN114599679A (zh) 2022-06-07
CN119798435A (zh) 2025-04-11
EP4013791A1 (en) 2022-06-22
WO2021026665A1 (en) 2021-02-18
CN114599679B (zh) 2024-10-18
EP4013791A4 (en) 2024-01-24
JP7840842B2 (ja) 2026-04-06
IL290509A (en) 2022-04-01
CA3147827A1 (en) 2021-02-18
KR20220078568A (ko) 2022-06-10
AU2020329092A1 (en) 2022-03-31
JP2022544308A (ja) 2022-10-17

Similar Documents

Publication Publication Date Title
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CL2021000738A1 (es) Proteínas de fijación a sirpa y métodos de uso de estas
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CO2019013669A2 (es) Anticuerpos anti-garp-tgf-β
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
MX2022001878A (es) Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
AR112048A1 (es) Anticuerpos cd47 y métodos de uso de los mismos
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
MX2020007527A (es) Tratamiento de enfermedades oftalmologicas.
MX2017016838A (es) Construcciones dirigidas a complejos de peptido de ny-eso-1/complejo principal de histocompatibilidad (mhc) y usos de los mismos.
MX374853B (es) Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso.
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
CO2022004743A2 (es) Anticuerpos dirigidos a flt3 y uso de los mismos
MX2018016096A (es) Anticuerpos antagonistas de anti-axl.
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso